TY - JOUR T1 - Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - 1476 LP - 1477 DO - 10.1136/ard-2022-222832 VL - 81 IS - 10 AU - Giuseppe A Ramirez AU - Lorenza Maria Argolini AU - Tommaso Schioppo AU - Savino Sciascia AU - Luca Moroni AU - Gabriella Moroni AU - Renato Alberto Sinico AU - Grazia Bonelli AU - Federico Alberici AU - Federica Mescia AU - Francesco Tamborini AU - Paolo Miraglia AU - Chiara Bellocchi AU - Lorenzo Beretta AU - Dario Roccatello AU - Enrica Paola Bozzolo AU - Roberto Caporali AU - Maria Gerosa AU - Lorenzo Dagna A2 - , Y1 - 2022/10/01 UR - http://ard.bmj.com/content/81/10/1476.abstract N2 - SARS-CoV-2-related disease (COVID-19) constitutes an ongoing challenge for public health. Vaccination campaigns have effectively reduced COVID-19-related morbidity and mortality, leading to less restrictive preventive measures. This has, however, led to worldwide absolute increasing rates of COVID-19 cases during the last months. Patients with multiorgan autoimmune disorders, including systemic lupus erythematosus (SLE) are at increased risk of morbidity due to SARS-CoV-2 infection and pandemic-related disruptions in public health services. Vaccination also constitutes a challenge for patients with SLE and other rheumatic disorders, who might develop dysfunctional immunisation responses due to disease-related and treatment-related factors. Poor humoral and cellular immunogenicity of current anti-SARS-COV-2 vaccines has been reported in patients with SLE and other immune-mediated diseases.1 2 However, less is known about the incidence and risk factors for breakthrough COVID-19 following vaccination.3 4 To address this issue, we analysed data from 452 patients with SLE (93% women) followed in seven Italian tertiary referral centres, who completed a primary vaccination cycle between January and November 2021. Data from patient history and status were collected during the last visit before and the first visit after the primary vaccination cycle. Postvaccination evaluations took place after a median (IQR) time of 3.9 (3.6–4.8) … ER -